The cytochrome P450 epoxygenase (CYP)-derived metabolites of arachidonic acid the epoxyeicosatrienoic acids (EETs) and hydrogen peroxide (H 2 O 2 ) both function as endothelium-derived hyperpolarizing factors (EDHFs) in the human coronary microcirculation. However, the relative importance of and potential interactions between these 2 vasodilators remain unexplored. We identified a novel inhibitory interaction between CYPs and H 2 O 2 in human coronary arterioles, where EDHF-mediated vasodilatory mechanisms are prominent. Bradykinin induced vascular superoxide and H 2 O 2 production in an endothelium-dependent manner and elicited a concentration-dependent dilation that was reduced by catalase but not by 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE), 6-(2-propargyloxyphenyl)hexanoic acid, sulfaphenazole, or iberiotoxin. However, in the presence of catalase, an inhibitory effect of these compounds was unmasked. In a tandem-bioassay preparation, application of bradykinin to endothelium-intact donor vessels elicited dilation of downstream endothelium-denuded detectors that was partially inhibited by donor-applied catalase but not by detector-applied EEZE; however, EEZE significantly inhibited dilation in the presence of catalase. EET production by human recombinant CYP 2C9 and 2J2, 2 major epoxygenase isozymes expressed in human coronary arterioles, was directly inhibited in a concentration-dependent fashion by H 2 O 2 in vitro, as observed by high-performance liquid chromatography (HPLC); however, EETs were not directly sensitive to oxidative modification. H 2 O 2 inhibited dilation to arachidonic acid but not to 11,12-EET. These findings suggest that an inhibitory interaction exists between 2 EDHFs in the human coronary microcirculation. CYP epoxygenases are directly inhibited by H 2 O 2 , and this interaction may modulate vascular EET bioavailability. (Circ Res. 2008;102:59-67.) Key Words: endothelium-derived hyperpolarizing factor Ⅲ hydrogen peroxide Ⅲ epoxyeicosatrienoic acid Ⅲ cytochrome P450 Ⅲ reactive oxygen species
T he vascular endothelium releases numerous vasodilatory substances, including nitric oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF). EDHF is an important modulator of vasomotor tone, particularly in the microcirculation. 1, 2 Despite more than a decade of investigation, the chemical identity of EDHF remains controversial, and multiple EDHFs have been proposed. Among these, substantial evidence now points to epoxyeicosatrienoic acids (EETs), [3] [4] [5] cytochrome P450 epoxygenase (CYP)-derived metabolites of arachidonic acid (AA), as EDHFs with another prominent candidate being the reactive oxygen species (ROS) hydrogen peroxide (H 2 O 2 ). 6, 7 It has been reported that a significant inhibitory interaction occurs between NO and EET, in which NO inhibits CYPmediated production of EET from AA. 8 Such an interaction presumably exists to conserve vasodilator substances, while at the same time providing a compensatory mechanism of dilation when one is impaired. It is not known whether interactions occur among substances proposed as EDHFs, or whether multiple EDHFs can contribute to vasomotor regulation in a singular vascular bed. Published studies from our laboratory suggest that both EETs and H 2 O 2 mediate dilation of human coronary arterioles (HCAs) in response to shear stress 9, 10 ; however, the relative importance of these EDHFs in receptor-mediated endothelium-dependent vasodilation and potential interactions between these EDHFs remain unexplored.
Because of the critical role of EDHFs in maintaining vasodilatory capacity when NO is impaired by oxidative stress, 11 it is essential to determine whether and to what extent EDHF-mediated dilation is altered by ROS. It is also essential to explore whether interactions occur between EDHFs that modulate the bioavailability of these vasodilators. The present study addresses both of these issues by focusing on H 2 O 2 , a compound that is both a ROS and a putative EDHF. We provide initial evidence of a predominant role of H 2 O 2 in receptor-mediated EDHF-dependent vasodilation and of an inhibitory interaction between 2 EDHFs (inhibition of CYPmediated EET production by H 2 O 2 ) in the human coronary microcirculation, where EDHF-mediated vasodilation is prominent. Specifically, we examined (1) whether EETs and/or H 2 O 2 contributes to bradykinin (BK)-induced dilation, (2) whether H 2 O 2 modulates the vascular effects of EET production, and (3) whether H 2 O 2 directly inhibits EET synthesis by CYPs.
Materials and Methods
Right atrial appendages were obtained as freshly discarded surgical specimens from 74 patients undergoing cardiopulmonary bypass procedures, 10 and 86 HCAs with a mean maximum internal diameter of 158Ϯ6 m were used. All protocols were approved by the local Institutional Review Boards. Demographic data and diagnoses were obtained from hospital records at the time of surgery, as summarized in the Table. Videomicroscopy Dilation of isolated, cannulated HCAs was observed by videomicroscopy. 10 Additional details are available in the online data supplement at http://circres.ahajournals.org.
Fluorescence Microscopy
Fluorescence detection of superoxide and H 2 O 2 was performed using dihydroethidium (DHE) and 2Ј,7Ј-dichlorodihydrofluorescein diacetate (DCFH), respectively. 9 Additional details are in the online data supplement.
Bioassay of HCAs
Bioassay of transferable vasodilator factors was performed using pairs of isolated HCAs from a single patient sample that were cannulated in tandem in a heated (37°C) bioassay dual-chamber perfusion apparatus, as diagrammed in Figure 3B . 12 Endotheliumintact "donor" arterioles were positioned upstream of endothelium-denuded "detector" arterioles in the presence of N -nitro-L-arginine methyl ester (L-NAME) (10 Ϫ4 mol/L, NO synthase inhibitor) and indomethacin (10 Ϫ5 mol/L, cyclooxygenase inhibitor). 10 Inflow pipettes were connected to a gravity-feed reservoir that maintained perfusion pressure at 80 mm Hg, and arterioles were equilibrated for 60 minutes. In some experiments, catalase (1000 U/mL) was present in the donor bath and/or 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE) (10 Ϫ5 mol/L, EET antagonist 5 ) was present in the detector bath. Endothelin-1 (5ϫ10 Ϫ10 to 10 Ϫ9 mol/L) was added to the detector bath to adjust tone to 50% to 70% of passive diameter. To ensure adequate endothelial denudation of the detector vessel (see the online data supplement for denudation procedure), BK (10 Ϫ6 mol/L) was added to the detector bath. Only vessels that dilated Ͻ5% were used for subsequent experiments. BK was then added to the donor bath, and internal diameter of the detector vessel was measured by videomicroscopy after reaching a new steady state (usually within 5 minutes following addition of BK). At the end of the experiments, maximum diameter was obtained by incubating detector vessels with papaverine (10 Ϫ4 mol/L). 9
Reverse-Phase High-Performance Liquid Chromatography
Microsomal or in vitro metabolism of 14 C-labeled AA or 3 H-labeled 14,15-EET was analyzed by reverse-phase high-performance liquid chromatography (HPLC). 5, 13 Additional details are in the online data supplement.
Statistical Analyses
Statistical analysis was performed as described in the online data supplement.
Results

Contribution of EETs and H 2 O 2 to BK-Induced Dilation
Previous studies indicate that both EETs and H 2 O 2 function as EDHFs in HCAs in response to shear stress 9,10 ; however, their contribution to agonist-induced vasodilation, if any, remains unexplored. To determine the relative contribution of EETs and H 2 O 2 to BK-induced dilation, internal diameter was measured in isolated HCAs using videomicroscopy. As shown in Figure 1 , BK elicited a concentration-dependent dilation that was not inhibited by EEZE (percentage of maximum dilation [%MD], 80Ϯ11 versus 94Ϯ1; ϪlogEC 50 , 7.2Ϯ0.2 versus 7.6Ϯ0.1 with vehicle; nϭ5 and 31, respectively; PϭNS), 6-(2-propargyloxyphenyl)hexanoic acid (PPOH) (selective CYP inhibitor 14 ; %MD, 90Ϯ4; ϪlogEC 50 , 7.4Ϯ0.2; nϭ7; PϭNS), or sulfaphenazole (selective CYP2C inhibitor 15 ; %MD, 87Ϯ5; ϪlogEC 50 , 7.3Ϯ0.2; nϭ6; PϭNS). Iberiotoxin, a specific inhibitor of large-conductance calcium-activated (BK Ca ) channels that reduces HCA dilation to exogenously applied EETs, 16 also had no effect on BKinduced dilation ( 
BK-Induced ROS Production in HCAs
The inhibitory effect of catalase indirectly suggests that H 2 O 2 mediates BK-induced dilation. To directly assess whether BK Figure 2 , that was abolished by endothelial denudation (0.81Ϯ0.16 and 0.83Ϯ0.13; nϭ4, respectively; PϽ0.05 versus intact HCAs), suggesting that the endothelium is essential in this response.
To determine whether the increase in DCFH fluorescence was attributable to H 2 O 2 and not other peroxide species, additional studies were performed in the presence of catalase. Importantly, catalase completely blocked the increase in DCFH but not DHE fluorescence (0.79Ϯ0.11 and 1.99Ϯ0.85; nϭ4; PϽ0.05 and PϭNS versus BK alone, respectively), indicating specificity for H 2 O 2 . These results are consistent with earlier reports indicating that catalase penetrates microvessels sufficiently to reduce intracellular DCFH fluorescence. 9, 17 Taken together, these results suggest that BK directly induces ROS production in an endotheliumdependent manner.
EETs Mediate BK-Induced Dilation When H 2 O 2 Is Reduced
In the presence of catalase, a prominent residual dilation to BK occurs, indicating the presence of an additional vasodilator mechanism. To determine whether EETs contribute to residual BK-induced dilation when H 2 O 2 is reduced, inhibitors were coadministered to HCAs with catalase ( Figure 3A) 
Modulation of Endothelial Release of EETs by H 2 O 2
To determine whether vascular bioavailability of EETs is modulated by H 2 O 2 , bioassay of transferable vasodilator factors was performed in HCAs. BK produced detector vessel dilation when added to donor vessels (%MD, 56Ϯ4; nϭ5; PϽ0.05 versus vehicle), as shown in Figure 3B and 3C, but not when added directly to detectors (%MD, 3Ϯ1; nϭ5; PϭNS versus vehicle; data not shown). Detector dilation to donor-applied BK was partially inhibited when catalase was added to the donor (%MD, 31Ϯ3; nϭ5; PϽ0.05 versus BK alone), and the residual dilation was abolished when EEZE was added to the detector (%MD, 7Ϯ6; nϭ5; PϽ0.05 versus BKϩdonor catalase). However, in the absence of donor-applied catalase, detector-applied EEZE had no effect (%MD, 53Ϯ8; nϭ5; PϭNS versus BK alone). These results suggest that EETs represent transferable endothelium-derived vasodilators that act directly on vascular smooth muscle cells (VSMCs) and that their release is inhibited by endogenous H 2 O 2 .
CYP Activity Is Suppressed by H 2 O 2
To determine the mechanism underlying the interaction between endogenous H 2 O 2 and EET-mediated dilation, we next examined whether H 2 O 2 interferes with EET signaling by inhibiting CYP-mediated EET production, by directly oxidizing EETs, and/or by interfering with the action of EETs on VSMCs.
To determine whether H 2 O 2 inhibits production of EETs by human CYPs, 14 C-AA metabolism was assessed in microsomes overexpressing CYP2C9 or CYP2J2, 2 isoforms that are expressed in HCA endothelium. 16 As shown in Figure 4 , CYP2C9 epoxygenase activity was inhibited in a concentration-dependent fashion by H 2 O 2 (IC 50 ϭ13Ϯ3 mol/ L). Importantly, synthesis of dihydroxyeicosatrienoic acids was not enhanced by H 2 O 2 , indicating that H 2 O 2 decreases EETs by interfering with their synthesis and not by enhancing their degradation to dihydroxyeicosatrienoic acids. Interestingly, CYP2J2 exhibited even greater sensitivity to H 2 O 2 (IC 50 ϭ0.3Ϯ0.05 mol/L) than CYP2C9. These results indicate that H 2 O 2 inhibits EET production by human CYPs in the low-to mid-micromolar range. To further explore the effect of H 2 O 2 on CYPs, 14 C-AA metabolism was assessed in microsomes from rat brain homogenates, a rich source of CYPs. 18 Exogenous ROS generation with xanthine plus xanthine oxidase similarly inhibited EET production from rat CYPs (data not shown). 
Discussion
This study is the first to investigate an inhibitory interaction between 2 EDHFs. The novel findings of the present study are three-fold. First, BK-induced vasodilation is predominantly mediated by endothelial production of H 2 
EETs and H 2 O 2 As Putative EDHFs
Although a large body of evidence points to EETs as EDHFs, 3 well. 6, 7, 9, 20 Although the existence of multiple EDHFs may be partially explained by differences between species or vascular beds, previous reports indicate that both EETs and H 2 O 2 function as EDHFs in vasomotor regulation of HCAs by shear stress. 9, 10 The present results provide additional evidence that these EDHFs both play a physiological role in a singular vascular bed. These results also suggest an explanation for the seemingly disparate reports that implicate 1 or the other as the dominant EDHF; ie, the predominance of EETs or H 2 O 2 as the mediator of the EDHF phenomenon may depend on the redox state of the endothelium.
Endothelial H 2 O 2 likely arises by dismutation of superoxide, which may originate from numerous sources, including xanthine oxidase, 21 NADPH oxidase, 22 uncoupled endothelial NO synthase, 21 mitochondria, 23 and CYPs. 24 In cardiovascular disease, several of these enzyme systems may be overly active 21, 22 or overexpressed, 25 leading to elevated vascular ROS generation. Both flow-induced 9 and BK-induced dilation of HCA are sensitive to inhibition by catalase, implicating a role for H 2 O 2 in these responses. Inhibitors of the mitochondrial electron transport chain reduce flow-induced dilation of HCAs, indicating that H 2 O 2 formation by shear stress requires mitochondria. 23 In contrast, studies in mouse 26 and human 27 mesenteric arteries indicate that BK-induced H 2 O 2 production requires Cu, Zn-superoxide dismutase, suggesting a cytosolic source of ROS in this context. Additional studies will therefore be necessary to identify the source of H 2 O 2 in HCAs in response to BK.
Interestingly, flow-induced vasodilation is blocked by CYP inhibitors, 10 unlike the results of the present study with BK, suggesting that differences in signaling and/or ROS generation exist between shear stress-and agonist-induced vasodilation. The effect of CYP inhibitors on flow-induced dilation is likely attributable to diminished production of EETs and not H 2 O 2 , as miconazole does not significantly reduce shearinduced H 2 O 2 production in HCAs (H.M., unpublished observation, 2001). It is not known whether CYP is a functionally relevant source of H 2 O 2 in response to BK, although the effects of CYP inhibitors on BK-induced dilation in the presence and absence of catalase indirectly suggest that CYP is a source of EETs and not H 2 O 2 in this model. However, future studies will be necessary to directly determine the source(s) of BK-induced ROS production.
Interestingly, iberiotoxin did not inhibit BK-induced vasodilation in the absence of catalase. We observed previously that H 2 O 2 -induced dilation of HCAs is reduced by a combination of charybdotoxin and apamin, 9 suggesting a role for K ϩ channels in this response; however, these inhibitors block not only BK Ca channels, but also intermediate-and smallconductance K Ca channels and voltage-dependent K v channels. 28 Although the present results with iberiotoxin indicate that H 2 O 2 -induced dilation does not require BK Ca channels, other K Ca channels and/or K v channels may contribute to this response.
Inhibitory Effect of H 2 O 2 on CYP Activity
H 2 O 2 is an important nonspecific redox modulator of cellular components, and elaborate antioxidant systems have evolved to minimize ambient H 2 O 2 , including catalase and glutathione peroxidase. Although less reactive than superoxide or other ROS, H 2 O 2 is capable of inactivating enzymes directly by oxidizing essential thiol groups, as occurs with glyceraldehyde-3-phosphate dehydrogenase. 29 H 2 O 2 also reduces the activity of some heme-containing enzymes, including CYP2B4 (a rabbit P450 monooxygenase), 30 by directly oxidizing and degrading the heme prosthetic group into monopyrrole and dipyrrole fragments that irreversibly bind to the protein. 31 Interestingly, P450BM-3 (a bacterial CYP) is highly unstable in the presence of H 2 O 2 . 32 Although the mechanism underlying this effect is uncertain, the redox sensitivity of the enzyme depends on a phenylalanine residue (Phe87) that extends into the heme pocket, 33 suggesting an interaction at or near the heme moiety. The present study indicates that H 2 O 2 directly inhibits human CYPs, but the specific underlying mechanisms and redox sites remain to be determined.
It has been reported that BK induces endothelial release of 1.5 mol/L H 2 O 2 from porcine coronary microvessels, 20 a concentration that inhibits CYP2J2 but not CYP2C9 in vitro. However, measurement of extracellular H 2 O 2 may underestimate acute H 2 O 2 production in endothelial cells, as intracellular antioxidant systems and extracellular dilution of H 2 O 2 by the perfusate may reduce the measurable extracellular concentration of H 2 O 2 . Indeed, intracellular antioxidants consume approximately 85% of H 2 O 2 given to Jurkat T-cells within a few seconds, 34 an antioxidant capacity similar to that of human vascular endothelial cells. 35 Therefore, intracellular H 2 O 2 may acutely rise as high as 10 mol/L in endothelial cells stimulated with BK, a concentration within the physiological range. 36 In addition, H 2 O 2 production may be greater in our model than in porcine coronary arterioles, because HCAs were obtained from patients with established cardiovascular disease, in whom ROS production may be enhanced. 37 Therefore, it is likely that intracellular H 2 O 2 is sufficiently high in HCAs to inhibit both CYP2J2 and CYP2C9. This hypothesis is indirectly supported by our results obtained with sulfaphenazole, where CYP2Cmediated dilation is seen only in the presence of catalase. However, determination of the physiologically relevant concentration range of intracellular H 2 O 2 in endothelial cells of HCAs will require development of new experimental techniques, because accurate quantification of H 2 O 2 within these cells is difficult using currently available assays. 
Potential Study Limitations
An inherent limitation of the current study is the lack of tissue from subjects who are completely free of disease, because such tissue is rarely obtainable. However, our model also presents the unique advantage of being able to study EETs and H 2 O 2 in the setting of chronic cardiovascular disease that cannot be adequately mimicked in animal models. In HCAs from subjects with coronary artery disease, endotheliumdependent dilation is mediated predominantly by EDHF, with little contribution by NO or prostacyclin 10 ; therefore, such tissue facilitates evaluation of EET and H 2 O 2 as EDHFs in a clinically relevant setting, with minimal confounding influence of other vasodilator factors. Although all experiments were performed in the presence of L-NAME and indomethacin to minimize NO and prostacyclin, respectively, it is possible that residual NO and/or prostacyclin may influence EDHF interactions in vivo.
Although the present study suggests that H 2 O 2 directly inhibits CYPs, the highly reactive hydroxyl radical, formed from H 2 O 2 by the iron-dependent Fenton reaction, may mediate this effect. Although iron-chelating agents are commonly used to assess the contribution of hydroxyl radical by preventing the Fenton reaction, deferoxamine abolished baseline CYP activity in our model (data not shown), thus preventing us from exploring this possibility. In addition, whereas EETs and AA are resistant to oxidation by H 2 O 2 in vitro, hydroxyl radical may oxidize these lipids in vivo, where iron is present. Alternative methods will therefore be necessary to evaluate the contribution of hydroxyl radical, if any, in this model.
An important limitation of the present study is the lack of direct EET measurements. Although numerous attempts were made to quantify EETs released from isolated HCAs using liquid chromatography electrospray-ionization mass spectrometry or HPLC, we were unable to quantify EETs in a consistent and reproducible manner. This may be attributable to an insufficient number of endothelial cells in a single arteriole (5-mm average length, 100-to 200-m internal diameter) and the limited number of arterioles that can be isolated from a single patient sample. Detection of EETs may also be hindered in these vessels by ambient ROS, which may be elevated in cardiovascular disease. 37 EET production has been demonstrated from animal microvessels 12, 38 ; however, these vessels were obtained from animals without cardiovascular disease. Not surprisingly, we were unable to demonstrate EET production from human microvascular or coronary artery endothelial cell cultures, a finding that is consistent with earlier reports that endothelial cells rapidly lose CYP expression and activity in culture. 39 An alternative explanation is that HCAs may not, in fact, produce EETs. Although this possibility cannot be ruled out, we believe this possibility is less likely, because HCAs produce a transferable vasodilator factor in a bioassay setup that is blocked by EEZE, a structural analog and antagonist of EET. Previous studies indicate that CYP2C9 and CYP2J2, as well as the EET-metabolizing soluble epoxide hydrolase (sEH) enzyme, are robustly expressed in HCA endothelium, 16 suggesting that HCAs are capable of not only producing EETs but also modulating their bioavailability. In addition, production of 11,12-EET has been demonstrated from diseased human left internal mammary arteries, 40 indicating that the human vasculature is capable of producing EETs in the milieu of cardiovascular disease.
Clinical Implications
With the expanding body of evidence implicating EETs as endogenous vasculoprotective agents, 41 considerable efforts have been made to identify the factors that determine EET bioavailability. Much has been learned about EET metabolism by sEH, ␤-oxidation, or esterification into the phospholipid membrane 41, 42 ; however, less is known about the factors that regulate EET production. The present study demonstrates that EET generation can be modulated by H 2 O 2 , an interaction that may increase in importance during cardiovascular disease, when ROS production is elevated. Although sEH inhibitors are now recognized as a potential therapeutic approach to enhance EET-mediated vasculoprotection, [43] [44] [45] the present study suggests that the efficacy of these agents may be limited by the redox status of the vasculature. Targeted antioxidant therapy, in conjunction with sEH inhibitors, may be beneficial to the diseased vasculature not only by limiting the proinflammatory effects of H 2 O 2 but also by enhancing the bioavailability of vasculoprotective EETs.
Conclusions
The present study supports a role for EETs and H 2 O 2 as EDHFs in the human coronary microcirculation and suggests that an inhibitory interaction exists between them. Human CYPs are directly inhibited by H 2 O 2 in a concentrationdependent manner. This effect of H 2 O 2 may modulate vascular EET bioavailability.
